Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Synergy Pharmaceuticals Inc's Subsidiary Files Form 10 For Planned Spin-Off Of FV-100 Assets-DJ


Thursday, 8 Aug 2013 06:00pm EDT 

Dow Jones reported that Synergy Pharmaceuticals Inc's Subsidiary announced the planned spin-off of its FV-100 assets into a separate publicly traded company. Synergy's newly formed subsidiary, ContraVir Pharmaceuticals, Inc., the Company which will hold the FV-100 assets, has filed a Form 10 Registration Statement with the U.S. Securities and Exchange Commission. The separation contemplates a 100% distribution of the ContraVir shares of common stock, now held by Synergy, to Synergy's stockholders on a pro-rata basis. 

Company Quote

2.83
-0.07 -2.41%
11:18am EST